As the population ages, there is a growing need for effective therapies for the treatment of neurological diseases. A limited number of therapeutics are currently available to improve cognitive function and research is limited by the need for in vivo models. Zebrafi sh have recently become a focus of neurobehavioral studies since larvae display neuropathological and behavioral phenotypes that are quantifi able and relate to those seen in man. Due to the small size of Zebrafi sh larvae, assays can be undertaken in 96 well plates and as the larvae can live in as little as 200 µl of fl uid, only a few milligrams of compound are needed for screening. Thus in vivo analysis of the effects of compounds can be undertaken at much earlier stages in the drug discovery process. This review will look at the utility of the zebrafi sh in the study of neurological diseases and its role in improving the throughput of candidate compounds in in vivo screens.
Introduction
Cognitive impairment manifests itself in a number of neurological diseases such as schizophrenia, Huntington's, Parkinson's, and Alzheimer's diseases. As the general population ages, there will be an increased incidence of these disease and disorders and thus a growing need for effective therapies for the treatment of the associated cognitive defi cits. A limited number of therapeutics are currently available to improve cognitive function and research is limited by the need for predictive in vivo models.
Introduction to zebrafi sh
Zebrafi sh have recently become a focus of neurobehavioral studies since larvae display learning, sleep, drug addiction, and other neurobehavioral phenotypes that are quantifi able and relate to those seen in man (Zhdanova et al 2001; Cahill 2002; Guo 2004; Orger et al 2004; Ninkovic et al 2006) . Furthermore, the organization of the zebrafi sh genome and the genetic pathways controlling signal transduction and development are highly conserved between zebrafi sh and man (Postlethwait et al 2000) . At seven days post fertilization (d.p.f.) the larvae are approximately 4 mm long. Due to this small size of the larvae, assays can be undertaken in 96 well plates and as the larvae can live in as little as 200 µl of fl uid; only a few milligrams of compound are needed for screening. Thus in vivo analysis of the effects of compounds can be undertaken at much earlier stages in the drug discovery process than has previously been possible, which is facilitated by the fact that zebrafi sh are dimethyl sulfoxide (DMSO) tolerant and readily absorb compounds from the water. The relative ease of maintaining large stocks of fi sh and its high fecundity can provide the investigator with large numbers of larvae to analyze. The above properties have established the zebrafi sh as an excellent model system that is relevant to studies of human diseases (Grunwald and Eisen 2002) . Conventional drug discovery has recently employed systematic, target-based high throughput screening in purifi ed proteins or cells as primary screens with in vivo models as tertiary screens in the cascade after more mechanistic cell assays.
While the in vitro screens have been successful at identifying small molecules affecting known mechanisms, there is still the need to identify modulators of complex in vivo phenotypes in the whole organism for less well understood pathways or those that only occur in a physiological/pathophysiological context. The advantages of using larval zebrafi sh described above allow higher throughput in vivo screening for phenotypic endpoints, and the utility of zebrafi sh in small molecule screening has been the subject of several reviews (MacRae and Peterson 2003; Zon and Peterson 2005; Murphey and Zon 2006; Berger and Currie 2007) . However, there are disadvantages to this approach. Namely, that uptake of compound into the zebrafi sh can be variable and should be measured for accurate interpretation of results (Berghmans et al 2008) and particularly to avoid false negatives, and the larval stage of the zebrafi sh may not be appropriate in all disease areas.
In a comparison of the zebrafi sh brain structure with man, there are some differences between teleosts and mammals. Notably, fi sh have smaller cerebral hemispheres and there are differences in the layout of the forebrain (extensively reviewed by Wullimann and Mueller 2004) and the structure and function of the optic tectum (Luque et al 2005) . However, the overall organisation of the zebrafi sh brain is similar to other vertebrates, having similarly defi ned areas such the hypothalamus and olfactory bulb, encompassing structures of the lateral pallium, which appear to be homologous to the mammalian hippocampus (Tropepe and Sive 2003) . In addition, the main neurotransmitter systems such as the cholinergic, dopaminergic, and noradrenergic pathways are present and have been mapped throughout the brain (Rink and Wullimann 2004; Wullimann and Mueller 2004) . Zebrafi sh have a developmentally regulated blood-brain barrier. Functional analysis using fl uorescent dyes and anatomical analysis by transmission electron microscopy provides evidence that the zebrafi sh blood brain barrier is functional at 10 d.p.f. (Goldsmith and Fleming 2007) . Additionally, it was also shown that zebrafi sh paralogues of P-glycoprotein (Pgp) are fi rst detected in the vasculature endothelium of the central nervous system (CNS) at 8 d.p.f., which coincides with the effl ux of the Pgp substrate, rhodamine 123 from the zebrafish brain. These data suggest that the zebrafi sh is a relevant model for the study of neurological diseases.
Zebrafi sh neurodegenerative disease models Huntington's disease
Huntington's disease (HD) is a monogenic polyglutamine (polyQ) neurodegenerative disorder which results in cognitive defi cits in attentional and executive functions along with defects in visual working memory (Montoya et al 2006) . Neurodegeneration occurs primarily in the striatal mediumsized spiny neurons which project to the substantia nigra and globus pallidus. HD has a prevalence of approximately 5 in 100,000 worldwide, the median age of onset being 39 (Cowan and Raymond 2006) . In zebrafi sh, the huntingtin (Htt) gene has been cloned and sequenced with a 3121 predicted amino acid protein, which has 70% identity with the human peptide sequence (Karlovich et al 1998) . Knockdown of Htt using morpholino technology disrupted a number of features of zebrafi sh development resulting in small head and eyes, delayed or paler pigmentation and colorless hypochromic blood (Lumsden et al 2007) . In a separate study, a 'Huntington's like' zebrafi sh was created by inserting mRNA of the N-terminal fragment of Htt with different length polyQ repeats linked to a GFP-fusion protein (Schiffer et al 2007) . The increasing polyQ length was associated with an increase in abnormalities and apoptosis in the embryos as early as 24 hours p.f. The embryos containing the Q102-GFP developed inclusions in the cytoplasm, which increased in size by incorporation of the soluble Q102 peptide leading to insoluble deposits. These fi ndings confi rmed a previous study where expression of poly Q56 or greater exhibited toxicity and abnormalities in the zebrafi sh embryos with inclusion bodies formed in more than 70% of embryos (Miller et al 2005) . These studies also investigated the effect of aggregation inhibitors which suggested that the prevention of aggregation did not reduce the toxic effect on the fi sh, implying that the formation of smaller intermediate aggregates were the main cause of toxicity. Thus, these models could be used to screen for novel compounds for the treatment of HD by evaluating either the prevention of aggregate formation, enhanced clearance of aggregates or the reduction in embryo death.
Alzheimer's disease
Alzheimer's disease (AD) is the most common cause of dementia, with nearly 50% of dementia cases worldwide being attributed to AD. The prevalence increases from 1.53% of the population between 65-69 years to as high as 30% between 80-85 years (Vandenberghe and Tournoy 2005; Mount and Downton 2006) . AD is characterized histopathologically by amyloid-beta (Aβ) containing plaques and intracellular neurofi brillary tangles consisting of abnormally phosphorylated tau protein in the brain (Selkoe 2000; Mudher and Lovestone 2002) . Cognitive impairments manifest themselves as progressive episodic memory loss and effects on executive functions, which are usually accompanied by mini-mental state examination scores below 24 (Vandenberghe and Tournoy 2005) . Zebrafi sh possess two homologues of amyloid precursor protein (APP) with good (about 70%) homology to human APP (Musa et al 2001) . Studies have demonstrated the presence of the functional γ-secretase machinery to produce Aβ in zebrafish (for a full review see Newman et al 2007) . Other studies have investigated the tau protein in zebrafi sh (Tomasiewicz et al 2002) . Microinjection of four repeat human tau GFP constructs into 1-2 cell stage embryos showed disruption to the cytoskeletal structure and tau traffi cking by 48 hours post injection. This eventually led to hyperphosphorylated fi brillar tau staining similar to that seen with neurofi brillary tangles in pathology of AD patients. These models offer the ability to screen for novel therapeutics that that decrease Aβ load and decrease the hyperphosphorylation seen in tauopathies.
Parkinson's disease
Although predominantly a movement disorder, there are a number of cognitive impairments associated with Parkinson's disease (PD) (Galvin 2006) . These include executive dysfunction and impaired memory retrieval and the prevalence increases from 2.7% per year at 55-64 years to 13.7% at 70-79 years. Parkinson's disease is characterized neuropathologically by degeneration of dopaminergic neurons and the appearance of intracytoplasmic inclusions called Lewy bodies. Genetically, six genes linked to Parkinsonism have been identifi ed: Parkin, DJ-1, PINK1, α-Synuclein, UCHL-1, and LRRK2 (Abeliovich and Beal 2006) . Of these genes two have been studied in zebrafi sh with preliminary work beginning on the others (Paquet et al 2006; Shankaran et al 2006) .
Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) was originally identifi ed in siblings with a strong family history of PD (Leroy et al 1998) . In zebrafi sh, UCH-L1 mRNA was expressed in neuronal cells at 1 d.p.f. (Son et al 2003) . UCH-L1 was detected in the diencephalon and ventral region of the mid and hindbrain, which are associated with motoneuron development (although which mammalian motoneurons these were correlated with was not investigated). Interestingly, in the ventral diencephalon, an area functionally homologous to the substantia nigra in humans, the UCH -L1 was co-expressed with tyrosine hydroxylase substantiating the association of UCH -L1 with dopaminergic neurons.
Patients with autosomal recessively inherited DJ-1 mutations typically present with early onset PD. In embryonic and adult zebrafi sh DJ-1 is expressed throughout the body with higher abundance in the brain, eyes, heart and muscle of the adult (Bretaud et al 2007) . The zebrafi sh DJ-1 protein has high homology with human (83%) and mouse DJ-1 (80%). Knockdown of DJ-1 in the zebrafi sh did not affect the number of dopaminergic neurons in a similar manner to the mouse DJ-1 null mutant (Chen et al 2005) . In keeping with the suggested role of DJ-1, the knockdown zebrafi sh embryos were more susceptible to oxidative stress and had signifi cantly elevated SOD1 levels. Furthermore, simultaneous knockdown of DJ-1 and p53 caused dopaminergic neuronal loss demonstrating a strong interaction between these genes.
The main pharmacological approach to studying PD in animal models has been using 1-methythl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) which reproduces some of the effects of idiopathic Parkinson's disease (Smeyne and Jackson-Lewis 2005) . Zebrafi sh embryos treated with MPTP demonstrated a loss of TH and DAT-expressing neurons which could be rescued using the monoamine oxidase-B inhibitor deprenyl (Bretaud et al 2004; Lam et al 2005; McKinley et al 2005) . A reduction was also seen in the locomotor activity mimicking motor effects seen in PD patients; however this did not always occur simultaneously with the reduction in dopaminergic cells (Salzmann et al 2006) and in the adult a reduction is seen in the locomotor activity without an effect being seen in dopaminergic cells (Anichtchik et al 2004) . The utility of these various models will aid screening for novel compounds for both the hereditary and the idiopathic forms of PD.
Schizophrenia
Schizophrenia affects approximately 1% of the world's population and is characterized by neuronal dysfunction resulting in defi cits in a number of different cognitive areas such as visual and verbal memory and learning and attention (Nuechterlein et al 2004; Tamminga 2006) . Patients with schizophrenia and other conditions including Huntington's disease have been shown to exhibit impaired prepulse inhibition (PPI) (Swerdlow et al 1995; Braff et al 2001) . PPI is a neurological phenomenon in which a weak prestimulus or prepulse suppresses the response to a subsequent startling stimulus and is highly conserved among vertebrates. A recent study of sensorimotor gating in zebrafi sh described an assay for PPI in 6 d.p.f. larvae (Burgess and Granato 2007) . In this study, the effective interstimulus interval for inhibition along with the dopaminergic and glutamergic modulation of PPI was found to be comparable to that in mammals. Again, using this paradigm will allow the screening of novel therapeutics for schizophrenia at an earlier stage of the drug discovery process.
Assays for assessing learning and memory in zebrafi sh
Mild cognitive impairment, a risk factor for AD, consists of a number of etiologies and is characterized by a slight impairment (usually memory) in cognitive function of everyday activities Best and Alderton (Levey et al 2006) . Its prevalence in epidemiological studies ranges from 3%-19% in adults over 65 years old, with half of adults diagnosed with MCI progressing to dementia (Gauthier et al 2006) . There have been a number of models developed to facilitate the study of learning and memory in zebrafi sh. Nonassociative learning has been studied in larval zebrafi sh by monitoring the reduction in a startle response to a series of acoustic stimuli (Best et al 2007) . This habituation to the stimuli was modulated by current therapies for improving cognitive ability in Alzheimer's disease patients, namely donepezil and memantine, as well as by the phosphodiesterase (PDE) 4 inhibitor rolipram, a compound shown to increase learning and memory in rodent studies. Associative learning has been demonstrated by visual discrimination in a T maze with food reward linked to certain colours (Colwill et al 2005) . The adult zebrafi sh learned to associate one of a pair of colours with food and reversal and extinction were also shown in this system. A T maze has also been used to determine the roles of glutamergic transmission (Swain et al 2004) and histamine in learning and memory in adult zebrafi sh (Peitsaro et al 2003) . Furthermore, adult zebrafi sh have been shown to display quick and reliable learning by swimming to certain locations within a tank to avoid adverse stimulus, such as a moving net (Arthur and Levin 2001) or electrical shocks (Xu et al 2007) and show cognitive fl exibility in that they show reversal when the contingencies are changed over. Active avoidance to avoid mild electrical shocks was used in a similar experimental paradigm to demonstrate the possible involvement of cell adhesion molecule L1.1 in memory consolidation (Pradel et al 2000) . A three compartment maze with a central chamber and a choice of moving to the left or right chambers has been used to demonstrate spatial and non spatial visual discrimination learning (Arthur and Levin 2001) and to demonstrate the improvement in learning in response to nicotine treatment (Levin et al 2006a) in adult zebrafi sh. A spatial alternation paradigm has been used to show that adult zebrafi sh learn to alternate between ends of the test tank for food reward, rapidly achieving high correct response levels (Williams et al 2002) . This behavior is recalled if the zebrafi sh are tested again after 10 days. This type of learning can be impaired in zebrafi sh treated with ethanol (10 mM) or lead (10 µM) for the fi rst 24 hours post fertilization of development as they demonstrated signifi cant learning and memory defi cits when treated in the three compartment maze assay (Carvan et al 2004) . The progress in the area of learning and memory experimental paradigms in zebrafi sh suggest the possible utility of this model organism in behavioral pharmacology studies.
Pharmacology mediating cognition
One of the key challenges with CNS drug discovery is the need to isolate specifi c areas of the brain mediating a particular disorder or disease. Therapies have become available for cognitive impairment, although these have been dominated by two classes of drug, acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) antagonists exemplifi ed by donepezil and memantine, respectively. Since a number of publications and reviews have covered these therapies, the pathways they mediate and their effects in both preclinical models ( , the latter part of this review will concentrate on four other interesting targets; these being phosphodiesterases, histamine H3 receptors, 5HT6 receptors, and AMPAkines, which are currently being investigated preclinically and the utility of zebrafi sh to aid in the characterization of these targets.
Phosphodiesterase inhibitors
The role of phosphodiesterases in cognition have been well documented (for reviews see Rose et al 2005; Hebb and Robertson 2007) . Currently, in mammals there are 11 distinct families encoding 21 genes. Of these, PDE 1, 2, 4, and 10 are primarily located in the mammalian brain. PDE1B and PDE10 are located in the striatum and expression levels of both were found to decline in the HD mouse models R6/1 and R6/2, suggesting a role for these PDEs in the defi cits associated with HD (Hebb et al 2004) . The PDE 4 A, B, and C isoforms are distributed throughout regions of the brain, with PDE4A and 4D observed in the hippocampus along with 4D, and all three isoforms were seen to different extents in the cortical regions (Cherry and Davis 1999) . Furthermore, although the levels of PDE4A were low in the substantia nigra there was no change in levels between the control and HD mice (Hebb et al 2004) . Since the levels of PDE4s may not change in Huntington's disease it may provide a viable target for the associated cognitive defi cits.
Treatment of rodents with rolipram, a nonselective PDE4 inhibitor, demonstrated either enhancement of memory and long term potentiation or a reversal of pharmacologically induced memory defi cit (Imanishi et al 1997; Barad et al 1998; Zhang and O'Donnell 2000) . Other studies with the PDE5 inhibitor sildenafi l, also demonstrated cognitive improvement in the object recognition and attenuated the scopolamine induced learning defi cit in mice suggesting this family as a possible therapeutic target (Prickaerts et al 2002; Devan et al 2004) . Futhermore, more recent studies have investigated PDE10A as a therapeutic target for treating schizophrenia and HD (Hebb et al 2004; Siuciak et al 2006) . However, despite the substantial data to support the role of PDEs in learning and memory, so far only the only reported studies for the clinical use of phosphodiesterase inhibitors, has been in the treatment of depression using rolipram (reviewed by Zhu et al 2001; Renau 2004) .
In zebrafi sh, 2',3'-cyclic-nucleotide 3'-phosphodiesterase was first reported as being induced in an optic nerve regeneration study (Ballestero et al 1999) . Further searches of the National Center for Biotechnology Information (NCBI) protein sequence fi nder revealed zebrafi sh possess proteins with similarity to the phosphodiesterases 1, 3-7, 9-11. Two enzymes of primary interest are the PDE4 (http://www.ncbi.nlm.nih.gov/BLAST, accession number: CAK10806), with an identity to the human PDE4C1 of 63%, rat 4D 67% and mouse 4C 61%, and PDE10A (http://www.ncbi.nlm.nih.gov/BLAST, accession number: NP 957396), which has an identity with the human, rat, and mouse PDE10A of 83% (for summary see Table 1 ). Specifi c orthologues of the other splice forms may also exist but have yet to be reported. As yet, little has been reported in zebrafi sh as to the effects of PDE inhibitors on learning and memory; though this lab has reported that rolipram enhances the acoustic startle response in 7 d.p.f. larval zebrafi sh and delays habituation to consecutives tones (Best et al 2007) . These effects in zebrafi sh are similar to those seen in previous rat studies (Kehne et al 1991) , suggesting the presence of functional phosphodiesterase 4 enzymes or at the very least high-affi nity rolipram binding sites. Clearly more investigations are needed to elucidate the distribution of PDEs in fi sh and their role in fi sh behavior and cognition.
Histamine 3 receptor antagonists
The histamine 3 (H3) receptor is a G protein coupled receptor identifi ed in the 1980s and pursued as a drug target for a number of indications (for reviews see Witkin and Nelson 2004; Esbenshade et al 2006; Bonaventure et al 2007) . H3 receptors are centrally located with mRNA distributed in regions connected to memory and learning, such as the hippocampus and cortex (Lovenberg et al 1999) . In recombinant receptor systems H3 receptors have been shown to have constitutive activity (reviewed by Arrang et al 2007) and research has centred on investigating inverse agonists/ antagonists for cognitive disorders. Thioperamide has been used to examine the effect of H3 receptor antagonists on learning and memory and clobenpropit has been shown to reverse scopolamine-induced learning defi cits as well as increasing social memory, attention and inhibitory avoidance. However, thioperamide and clobenpropit impair fear conditioning suggesting H3 antagonists may be specifi c in their role in mediating cognition (Passani et al 2004; Witkin and Nelson 2004; Esbenshade et al 2006; Bonaventure et al 2007) . A number of pharmaceutical companies have programs based around H3 antagonists with clinical candidates reported in Phase I (see Esbenshade et al 2006) .
Three histamine receptors H1, H2, and H3 have been cloned and expressed in zebrafi sh (Peitsaro et al 2007) . When compared with the distribution in mammalian brain, the histaminergic neurons are more tightly located around the posterior recess and are more ventral to the mammillary body than in rodents. However, the rostrocaudal distribution is very similar to that seen in the rat and overall the projections patterns are highly conserved (Kaslin and Panula 2001) . Comparison of the H3 receptor peptide sequence showed 50% identity with the human (see Table 1 ) (Peitsaro et al 2007) , and binding studies demonstrated the H3 receptor was expressed throughout the zebrafi sh brain with the greatest intensity in the optic tectum and hypothalamus (Peitsaro et al 2000) . Zebrafi sh at 5 d.p.f. treated with thioperamide (100 µM) demonstrated a decrease in locomotor activity although no toxicity assessment was given to determine whether this decrease was an effect was specifi c antagonism or a reduction due to generalised toxicity. Other studies in goldfi sh have demonstrated involvement of H1 and H2 in inhibitory avoidance (Cofi el and Mattioli 2006) .
5HT6 receptor antagonists
5-Hydoxytryptamine (5-HT) receptors so far are composed of seven different subtypes which have been implicated in mediating cognition (Meneses 1999 (Meneses , 2007 . They are all found in areas of the brain connected with learning and memory, but attention has focussed on 5-HT6, which appears to have a greater role in long-term memory (for review see Mitchell and Neumaier 2005) . A number of antagonists (eg, RO4368554, SB-271046) have been shown to reverse scopolamine-induced defi cits in passive avoidance assays in rats as well as enhancing object recognition (Foley et al 2004; Mitchell and Neumaier 2005; Hirst et al 2006; Schreiber et al 2007) , although the consistency of the effect at this target has been disputed, which raises questions as to brain penetrance and selectivity of the various compounds used (Russell and Dias 2002) . Again, despite the literature supporting their effect in learning and memory, there are currently no reports of clinical trials for 5HT6 antagonists. In zebrafi sh, 5-HT neurons are expressed in the spinal cord as early as 1 d.pf. with populations in the telencephalon, hindbrain and throughout the brain by 5 d.p.f. (Drapeau et al 2002; McLean and Fetcho 2004) . In the adult these neurons cluster in the area of the hypothalamus and habenula (Kaslin and Panula 2001) . A search of the NCBI protein sequence fi nder database and blast search shows that zebrafi sh have at least three recognised 5-HT receptors namely 1, 2 and 7 (http://www.ncbi.nlm.nih.gov/BLAST). This has been confi rmed with studies using methysergide a 5-HT 1,2,7 antagonist which modulated locomotor activity in larval zebrafi sh (Drapeau et al 2002; Brustein and Drapeau 2005) . Studies in goldfi sh have demonstrated the presence of 5-HT1A in the retina (Schmeer et al 2001) . Interestingly, a blast search using the human 5-HT6 peptide sequence revealed 54% identity with a hypothetical protein (accession number: XP 696681) which also has 52% and 50% identity with the rat and mouse 5-HT6 sequences respectively (see Table 1 ).
AMPA receptor potentiators
Alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors are glutamate receptors comprising four different subunits GluRA1-A4, are found throughout the CNS mediating fast excitatory transmission (for a comprehensive review see O'Neill et al 2004) . Early studies have shown the presence of multiple AMPA receptors in the CA1/CA2 region of the hippocampus suggesting this as a target for cognition (Wenthold et al 1996) . Ampakines are a diverse class of compounds which positively modulate glutamateric AMPA receptors with pyrrolidones (eg, piracetam) and piperidines (CX516) being examples (see O'Neill et al 2004; O'Neill and Dix 2007) . These compounds have been studied in a number of different rodent memory tasks such as spatial memory, delayed-nonmatch-to sample and extinction learning and have been shown to improve performance (Staubli et al 1994; Hampson et al 1998; Zushida et al 2007) . However, despite some early encouraging data (Lynch and Gall 2006) , recent clinical results have been mixed with the ampakine farampator increasing short-term memory trial of the symbol digit recall test in elderly patients (Wezenberg et al 2007) whereas CX516 used as an add-on therapy did not alter the composite cognitive score compared to the placebo group in schizophrenic patients (Goff et al 2007) or improve cognitive outcomes in patients with fragile X syndrome (Berry-Kravis et al 2006) suggesting these compounds may not have been dosed adequately or that they need to be used more selectively for cognitive impairments.
Zebrafi sh possess the AMPA receptors subunits GluR1-4 with each one consisting of a subtype A and B (NCBI protein database; http://www.ncbi.nlm.nih.gov/sites/entrez). A blast search between the subtypes shows a similarity between the A and B subtypes ranges from 82% for GluR1, 88% GluR3 to 92% for GluR2 and 4. Compared with human, rat, and mouse, the zebrafi sh receptors have very good identity, the 1A subtype has 71% identity with the human, rat, and mouse GluR1 sequences. The GluR2-4A receptors have higher identities with human, rat and mouse of between 85%-90% with the equivalent protein sequence (see Table 1 ). AMPA receptors have been found and studied in the retina, hindbrain, spinal cord, and Mauthner neurons of zebrafi sh (Ali et al 2000; Yazulla and Studholme 2001; Patten and Ali 2007) . They are also associated with the neuromuscular junction in zebrafi sh (Todd et al 2004) . Not much has been reported in the zebrafi sh literature as to the affect of AMPAkines on their learning and memory; however studies on nonassociative learning in this lab investigating piracetam have found that it increased the ASR and prolonged the habituation (unpublished data) similar to the other cognition enhancers tested.
Conclusion
It is now recognised that zebrafi sh possess a great deal of similarity to mammals and are an extremely useful model for screening compounds at several stages of the drug discovery process (see Figure 1) . As more is reported on the effi cacy models in zebrafi sh its utility as an early stage screening tool for the discovery of CNS therapeutics should enable increased throughput of in vivo analysis of novel compounds for neurological disorders. In this review we have described the application of the zebrafi sh models to neurodegenerative disorders, schizophrenia and learning and memory. Several of these diseases affect an aging population and are adult onset raising questions as to the appropriateness of using a rapidly developing larval system. However, early phenotypes are observable and in comparison with rodents the zebrafi sh larvae are not foetal but are closer to juveniles in that the nervous system is mature, organs are functioning and tissue architecture is fully developed by the time at which many of the assays are performed. In this review we have also described four validated pharmacological targets which are being investigated preclinically for impaired learning and memory; phosphodiesterases, histamine 3, 5HT-6 and AMPA, and have illustrated how zebrafi sh may be used in the assessment of these targets. As more information is reported on neurological assays in zebrafi sh, the utility of this model organism as an early stage screening tool for CNS disorders should help increase in vivo throughput and ameliorate the cost associated with drug screening in mammals. 
